Concert Pharmaceuticals Inc., of Lexington, Mass., presented preclinical data showing C-10068 has activity in models of epilepsy, neuroprotection and neuropathic pain. The drug showed anti-convulsant activity in models of both grand mal and partial seizures, and it inhibited hippocampal neurotoxicity and demonstrated neuroprotective effects. The data were presented at the Antiepileptic Drug Trials XI Conference.